e-Bio is a clinical-stage medical device company developing an innovative solution to stop preterm labor. After years of animal studies, e-Bio was granted authorization from the FDA for studies in humans, which we are currently conducting.
DEFINITION AND CAUSES
Premature births are the most common complication of pregnancy. It affects 10% of all pregnancies. Of those deliveries, 70% are caused by preterm labor a condition defined when labor starts before 37 weeks of pregnancy. There are many causes of premature births, and many are related to the trigger of preterm labor.
e-Bio's proprietary technology is based on the concept of electric inhibition, meaning that by using an electric signal we are able to affect uterine contractions. By applying this stimulation towards the women's uterus, we can diminish or stop contractions on preterm pregnancies.
e-Bio is currently working with different prototypes aiming to find the optimal solution for the final product. e-Bio have FDA's IDE for use of the device in clinical trials.
STUDIES AND RESULTS
e-Bio's co-founders have extensively published data regarding electric inhibition of uterine contractions. From early animal studies to more recent human trials currently being conducted.
The results are very encouraging, showing e-Bio's device was able to diminish or stop uterine contractions on preterm labor patients.
The first phase trial, currently on the way, is supported by a grant from March of Dimes, one of the largest organizations on the fight for the health of all moms and babies.
Where the Passion Begins
DENIS SCHAPIRA WAJMAN
Chief Medical Officer
Chief Scientific Officer